PO.TB10.05 · 肿瘤生物学

补铁可纠正胰腺导管腺癌中慢性病贫血

Iron supplementation rescues anemia of chronic disease in pancreatic ductal adenocarcinoma

海报缩略图:补铁可纠正胰腺导管腺癌中慢性病贫血
编号 2099 展板 29 时间 4/20 09:00–12:00 区域 Section 26 主讲 Yichi (Tony) Zhang, BS;MS;PhD
分会场 Aging and Host Determinants of Tumor Progression: The Macroenvironmental Axis
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Yichi (Tony) Zhang1, Cindy Pyo1, Anna Barbeau1, Davey Feng1, Amit Roopan1, Matthew Vander Heiden1, Kendra Libby2, Alison Epstein Ringel3

1Koch Inst. for Integrative Cancer Research at MIT, Cambridge, MA,2Ragon Institute, Cambridge, MA,3Massachusetts Institute of Technology (MIT), Cambridge, MA

摘要 Abstract

中文摘要
胰腺癌是一种毁灭性的恶性肿瘤,其发病率正在上升,且几乎普遍预后不良。我们发现胰腺癌患者的缺铁率很高,并且与这些患者中贫血的高患病率相关。从进化角度来看,慢性病贫血是一种在机体对炎症性损伤(如感染)做出反应时出现的状况:机体将铁从循环中隔离,储存于外周组织(如肌肉)中,使这些铁无法被病原体利用。我们最近的初步数据提示,胰腺癌可能作为炎症刺激引起铁调节异常和贫血。对一大队列胰腺癌患者的分析显示,胰腺癌患者的铁和血红蛋白在早期即出现下降,提示铁代谢失调。在小鼠中建立胰腺癌模型时,也观察到血红蛋白和铁的下降,以及循环中hepcidin的升高。有趣的是,给荷胰腺癌小鼠补铁可改善贫血。在机制上,我们希望了解为何PDAC小鼠发生贫血,并分析了骨髓中表达Ter119的红细胞的分化和成熟。我们发现PDAC小鼠红系成熟无缺陷,因此红细胞生成缺陷不太可能是PDAC贫血的原因。我们还检测了F4/80阳性巨噬细胞表面的Ter119表达作为噬血作用的衡量指标,发现PDAC中Ter119阳性巨噬细胞减少,因此骨髓中的噬血作用也不是PDAC贫血的原因。我们发现hepcidin等铁隔离蛋白在整个PDAC进展过程中升高,肿瘤中存在铁隔离,并且在PDAC过程中我们发现多种不同细胞类型和组织存在铁隔离。已知hepcidin可引起巨噬细胞中的铁隔离,而巨噬细胞是体内血红素和血红蛋白合成的最大铁回收和供给来源。此外,我们观察到PDAC小鼠骨髓中巨噬细胞数量减少。因此,我们提出PDAC导致巨噬细胞的铁回收减少,从而引起慢性病贫血。因此,补铁足以纠正PDAC中的贫血。
查看英文原文 English abstract
Pancreatic cancer is a devastating malignancy that is rising in incidence and has nearly universal poor outcomes. We find rates of iron deficiency are high in pancreatic cancer patients and track with the high prevalence of anemia in these patients. From an evolutionary perspective, anemia of chronic disease is a condition seen where our bodies respond to an inflammatory insult, such as an infection, by sequestering iron from circulation to store the iron in peripheral tissues, such as muscle, to make this iron unavailable for pathogens. Our recent preliminary data suggest pancreatic cancer may act as the inflammatory stimulus to cause iron dysregulation and anemia. Analysis of a large cohort of pancreatic cancer patients shows both iron and hemoglobin decrease early in pancreatic cancer patients, suggesting of dysregulated iron metabolism. When pancreatic cancer is modeled in mice, decreases in hemoglobin and iron are also observed, as are increases in circulating hepcidin. Interestingly, supplementing mice with pancreatic cancer with iron improves anemia. Mechanistically, we want to understand why mice with PDAC develop anemia and analyzed Ter119-expressing erythrocyte differentiation and maturation in the bone marrow. We found that there is no defect in erythroid maturation in PDAC mice therefore its unlikely that defective erythropoiesis is the cause for anemia in PDAC. We also profiled Ter119-expression on the surface of F4/80-positive macrophages as a measure of hemophagocytosis and found that there is decreased Ter119-positive macrophages in PDAC so hemophagocytosis in the bone marrow is not the caused of anemia in PDAC. We find that iron-sequestering proteins such as hepcidin are increased throughout PDAC progression and iron sequestration in tumors and we find iron sequestration by many different cell types and tissues during PDAC. Hepcidin is known to cause iron sequestration in macrophages, which are the largest source of iron recycling and supply for heme and hemoglobin synthesis in the body. Furthermore, we observed decreased macrophage numbers in the bone marrows of PDAC mice. Hence, we proposed that PDAC leads to reduced iron-recycling by macrophages and this causes anemia of chronic disease. Therefore, iron supplementation is sufficient to rescue anemia in PDAC.
利益披露 Disclosure
Y. Zhang, None.. C. Pyo, None.. A. Barbeau, None.. D. Feng, None.. A. Roopan, None.. M. Vander Heiden, None.. K. Libby, None.

← 返回 AACR 2026 检索